Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02199184
Title Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

B-cell lymphoma

acute lymphoblastic leukemia

Burkitt lymphoma


Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.